Emerging Role of MicroRNAs in Drug-Resistant Breast Cancer
Emerging Role of MicroRNAs in Drug-Resistant Breast Cancer
复制标题
DOI：
10.3727/105221611x13176664479287
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Jacob, Samson T.
中科院分区：
文献类型：
--
作者：
Majumder, Sarmila;Jacob, Samson T.
对常用治疗药物的内在或获得性耐药性是治疗癌症患者的主要挑战。数十年的研究揭示了几种可能导致乳腺癌耐药性的独特且常见的机制。最近的研究揭示了小非编码 RNA（称为 microRNA (miRNA)）的调节作用，过去它们被认为是“垃圾”RNA。实际上，正常和疾病条件下细胞生理学的所有方面都被发现受到 miRNA 的调节。在这篇综述中，我们将讨论 miRNA 谱在耐药性发展过程中如何改变，以及 miRNA 在赋予常用治疗药物耐药性方面发挥的关键调节作用。希望进一步的研究将导致使用这些差异表达的 miRNA 作为预后和预测标记，以及克服耐药性的新治疗靶点。
Intrinsic or acquired resistance to commonly used therapeutic agents is a major challenge in treating cancer patients. Decades of research have unraveled several unique and common mechanisms that could contribute to drug resistance in breast cancer. Recent studies unraveled the regulatory role of small noncoding RNA, designated as microRNA (miRNA), that were thought to be "junk" RNA in the past. Practically all aspects of cell physiology under normal and disease conditions were found to be regulated by miRNAs. In this review, we will discuss how miRNA profile is altered upon resistance development and the critical regulatory role miRNAs play in conferring resistance to commonly used therapeutic agents. It is hoped that further studies will lead to use of these differentially expressed miRNAs as prognostic and predictive markers, as well as novel therapeutic targets to overcome resistance.